Filing Flows › Aquestive Therapeutics (AQST) › Q3 2026 › vs Q2 2026
Aquestive Therapeutics (AQST) Q3 2026 vs Q2 2026 (quarter over quarter)
Aquestive Therapeutics's revenue fell $6.3M (-45%) from $13.8M in Q2 2026 to $7.6M in Q3 2026. The biggest changes: Manufacture and supply revenue −$5.3M (-44%); Co-development and research fees −$508K (-87%); License and Royalty Revenue −$502K (-38%).
Aquestive Therapeutics, Q3 2026: revenue $7.6M (-41% year over year), operating margin -191.5%, net loss $16.5M, operating cash flow −$7.0M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Manufacture and supply revenue | $6.7M | $11.9M | −$5.3M | -44% |
| License and Royalty Revenue | $824K | $1.3M | −$502K | -38% |
| Co-development and research fees | $74K | $582K | −$508K | -87% |
| Revenue | $7.6M | $13.8M | −$6.3M | -45% |
| Net loss | $16.5M | $22.9M | −$6.4M | -28% |
| Costs & expenses | $24.1M | $36.7M | −$12.6M | -34% |
| Operating costs | $22.0M | $22.0M | −$16K | -0.1% |
| Interest & other, net | $2.0M | $14.6M | −$12.6M | -86% |
| Cost of revenue | $3.6M | $4.0M | −$411K | -10% |
| Research & development | $4.3M | $4.0M | $289K | +7% |
| SG&A | $14.2M | $14.1M | $106K | +0.8% |
| Operating cash sources | $16.5M | $22.9M | −$6.4M | -28% |
| Depreciation | $156K | $136K | $20K | +15% |
| Share-based compensation | $2.1M | $2.9M | −$769K | -27% |
| Working capital & other | $7.2M | $10.4M | −$3.2M | -31% |
| Cash used in operations | $7.0M | $9.4M | −$2.4M | -25% |
| Net loss absorbed | $16.5M | $22.9M | −$6.4M | -28% |
Questions
How much did Aquestive Therapeutics's revenue grow quarter over quarter in Q3 2026?
Aquestive Therapeutics's revenue fell $6.3M (-45%) from $13.8M in Q2 2026 to $7.6M in Q3 2026.
What drove Aquestive Therapeutics's revenue change in Q3 2026?
Manufacture and supply revenue −$5.3M (-44%); Co-development and research fees −$508K (-87%); License and Royalty Revenue −$502K (-38%).